Bhargavi Duvvuri1, Al Anoud Baddour1, Kevin D Deane2, Marie L Feser2, J Lee Nelson3, M Kristen Demoruelle2, Christian Lood4. 1. Department of Medicine, Division of Rheumatology, University of Washington, Seattle, WA, USA. 2. Division of Rheumatology, University of Colorado-Denver, Aurora, CO, USA. 3. Department of Medicine, Division of Rheumatology, University of Washington, Seattle, WA, USA; Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 4. Department of Medicine, Division of Rheumatology, University of Washington, Seattle, WA, USA. Electronic address: CLood@medicine.washington.edu.
Abstract
OBJECTIVES: Literature suggests that neutrophils of patients with rheumatoid arthritis (RA) are primed to respond to N-formyl methionine group (formylated peptides). Animal models indicate that formylated peptides contribute to joint damage via neutrophil recruitment and inflammation in joints. Non-steroidal anti-inflammatory drugs are also known to inhibit formyl peptide-induced neutrophil activation. The predominant source of formylated peptides in sterile inflammatory conditions like RA is mitochondria, organelles with prokaryotic molecular signatures. However, there is no direct evidence of mitochondrial formyl peptides (mtNFPs) in the circulation of patients with RA and their potential role in neutrophil-mediated inflammation in RA, including their clinical significance. METHODS: Levels of mtNFPs (total fMet, MT-ND6) were analyzed using ELISA in plasma and serum obtained from patients in 3 cross-sectional RA cohorts (n = 275), a longitudinal inception cohort (n = 192) followed for a median of 8 years, and age/gender-matched healthy controls (total n = 134). Neutrophil activation assays were done in the absence or presence of formyl peptide receptor 1 (FPR1) inhibitor cyclosporine H. RESULTS: Elevated levels of total fMet were observed in the circulation of patients with RA as compared to healthy controls (p < 0.0001) associating with disease activity and could distinguish patients with the active disease from patients with inactive disease or patients in remission. Baseline levels of total fMet correlated with current and future joint involvement, respectively and predicted the development of rheumatoid nodules (OR = 1.2, p = 0.04). Further, total fMet levels improved the prognostic ability of ACPA in predicting erosive disease (OR of 7.9, p = 0.001). Total fMet levels correlated with markers of inflammation and neutrophil activation. Circulating mtNFPs induced neutrophil activation in vitro through FPR1-dependent mechanisms. CONCLUSIONS: Circulating mtNFPs could be novel biomarkers of disease monitoring and prognosis for RA and in investigating neutrophil-mediated inflammation in RA. We propose, FPR1 as a novel therapeutic target for RA.
OBJECTIVES: Literature suggests that neutrophils of patients with rheumatoid arthritis (RA) are primed to respond to N-formyl methionine group (formylated peptides). Animal models indicate that formylated peptides contribute to joint damage via neutrophil recruitment and inflammation in joints. Non-steroidal anti-inflammatory drugs are also known to inhibit formyl peptide-induced neutrophil activation. The predominant source of formylated peptides in sterile inflammatory conditions like RA is mitochondria, organelles with prokaryotic molecular signatures. However, there is no direct evidence of mitochondrial formyl peptides (mtNFPs) in the circulation of patients with RA and their potential role in neutrophil-mediated inflammation in RA, including their clinical significance. METHODS: Levels of mtNFPs (total fMet, MT-ND6) were analyzed using ELISA in plasma and serum obtained from patients in 3 cross-sectional RA cohorts (n = 275), a longitudinal inception cohort (n = 192) followed for a median of 8 years, and age/gender-matched healthy controls (total n = 134). Neutrophil activation assays were done in the absence or presence of formyl peptide receptor 1 (FPR1) inhibitor cyclosporine H. RESULTS: Elevated levels of total fMet were observed in the circulation of patients with RA as compared to healthy controls (p < 0.0001) associating with disease activity and could distinguish patients with the active disease from patients with inactive disease or patients in remission. Baseline levels of total fMet correlated with current and future joint involvement, respectively and predicted the development of rheumatoid nodules (OR = 1.2, p = 0.04). Further, total fMet levels improved the prognostic ability of ACPA in predicting erosive disease (OR of 7.9, p = 0.001). Total fMet levels correlated with markers of inflammation and neutrophil activation. Circulating mtNFPs induced neutrophil activation in vitro through FPR1-dependent mechanisms. CONCLUSIONS: Circulating mtNFPs could be novel biomarkers of disease monitoring and prognosis for RA and in investigating neutrophil-mediated inflammation in RA. We propose, FPR1 as a novel therapeutic target for RA.
Authors: Ritika Khandpur; Carmelo Carmona-Rivera; Anuradha Vivekanandan-Giri; Alison Gizinski; Srilakshmi Yalavarthi; Jason S Knight; Sean Friday; Sam Li; Rajiv M Patel; Venkataraman Subramanian; Paul Thompson; Pojen Chen; David A Fox; Subramaniam Pennathur; Mariana J Kaplan Journal: Sci Transl Med Date: 2013-03-27 Impact factor: 17.956
Authors: H Mielants; S Goemaere; M De Vos; K Schelstraete; K Goethals; M Maertens; C Ackerman; E M Veys Journal: J Rheumatol Date: 1991-03 Impact factor: 4.666
Authors: Luc H Boudreau; Anne-Claire Duchez; Nathalie Cloutier; Denis Soulet; Nicolas Martin; James Bollinger; Alexandre Paré; Matthieu Rousseau; Gajendra S Naika; Tania Lévesque; Cynthia Laflamme; Geneviève Marcoux; Gérard Lambeau; Richard W Farndale; Marc Pouliot; Hind Hamzeh-Cognasse; Fabrice Cognasse; Olivier Garraud; Peter A Nigrovic; Helga Guderley; Steve Lacroix; Louis Thibault; John W Semple; Michael H Gelb; Eric Boilard Journal: Blood Date: 2014-07-31 Impact factor: 22.113
Authors: Yann L C Becker; Bhargavi Duvvuri; Paul R Fortin; Christian Lood; Eric Boilard Journal: Nat Rev Rheumatol Date: 2022-09-29 Impact factor: 32.286
Authors: Despina Michailidou; Bhargavi Duvvuri; Runa Kuley; David Cuthbertson; Peter C Grayson; Nader A Khalidi; Curry L Koening; Carol A Langford; Carol A McAlear; Larry W Moreland; Christian Pagnoux; Philip Seo; Ulrich Specks; Antoine G Sreih; Kenneth J Warrington; Tomas Mustelin; Paul A Monach; Peter A Merkel; Christian Lood Journal: Arthritis Res Ther Date: 2022-06-29 Impact factor: 5.606
Authors: Martin Ingi Sigurdsson; Hirotada Kobayashi; Karin Amrein; Kiichi Nakahira; Angela J Rogers; Mayra Pinilla-Vera; Rebecca M Baron; Laura E Fredenburgh; Jessica A Lasky-Su; Kenneth B Christopher Journal: Crit Care Date: 2022-10-19 Impact factor: 19.334
Authors: Liu Cui; Jing Weiyao; Su Chenghong; Liu Limei; Zhang Xinghua; Yuan Bo; Du Xiaozheng; Wang Haidong Journal: Front Med (Lausanne) Date: 2022-09-23
Authors: Runa Kuley; Ryan D Stultz; Bhargavi Duvvuri; Ting Wang; Marvin J Fritzler; Roger Hesselstrand; J Lee Nelson; Christian Lood Journal: Front Immunol Date: 2022-01-05 Impact factor: 7.561